Skip to main content
Fig. 3 | BMC Research Notes

Fig. 3

From: Screening of melatonin, α-tocopherol, folic acid, acetyl-l-carnitine and resveratrol for anti-dengue 2 virus activity

Fig. 3

Effect of resveratrol on DENV2 infection of HEK293T/17 and HepG2 cells. The cytotoxicity of resveratrol was assessed in a uninfected HEK293T/17 (left panel) and HepG2 (right panel) and b DENV 2 infected HEK293T/17 (left panel and HepG2 (right panel) cells. Infected and uninfected cells were incubated with various concentration of resveratrol for 24 h and viability was assessed using MTT assay. The experiments were performed independently in triplicate in parallel with control treatments and mock. A negative of cells plus 5% DMSO in complete media was included. The standard deviation (SD) of mean are presented as error bars. c HEK293T/17 cells were infected with DENV 2 at MOI 0.5 and 2, and then treated with or without 25 or 50 μM resveratrol or with vehicle only. d HepG2 cells were infected with DENV 2 at MOI 2 and 5 and then treated with or without 50 or 100 μM resveratrol or with vehicle only. At 24 h post infection cells were analyzed by flow cytometry to determine the percentage infection. All experiments were undertaken independently in triplicate. Error bar showed mean ± SD (*p value ≤ 0.05). e For infections showing a significant difference in infection from c and d, the supernatants at 0 h (input virus; 0 h) and 24 h post infection (24 h) were assayed for virus titer by standard plaque assay. f HEK293T/17 cells were infected with DENV 2 at MOI 2 or 0.01 and treated with increasing concentrations of resveratrol or treated with vehicle and at 24 h post infection supernatants were assayed for virus titer by standard plaque assay. All experiments were undertaken independently in triplicate. Error bar showed mean ± SD (*p value ≤ 0.05, **p value ≤ 0.01)

Back to article page